Press releases
Press Releases
Stay up to date with the latest news, announcements, and developments from EVOQ.
April 9, 2025
The "Father of modern food and drug law," Peter Hutt, joins EVOQ board of directors
Hutt brings decades of regulatory insight to help advance nanoparticle technology platform
January 31, 2025
EVOQ secures strategic investment from global business leader & philanthropist Tony Robbins to advance next-generation antimicrobial metamaterial technology
Tony Robbins invests in transformational metamaterial platform technology, EVOQ.
November 20, 2024
EVOQ expands antimicrobial medical device platform, demonstrates efficacy across multiple device applications
Four integration methods aim to combat healthcare-associated infections & improve device performance
July 16, 2024
EVOQ EVQ-218 metamaterial addresses critical gap in fight against antibiotic-resistant bacteria
Non-ionic EVQ-218 demonstrates success in combating leading pathogens without triggering antimicrobial resistance (AMR)
May 15, 2024
EVOQ Bio completes successful pre-investigational new drug meeting with FDA for development of inhaled therapeutic to treat pulmonary infections
Major milestone for EVŌQ Nano biotech arm targeting antibiotic-resistant bacterial infections linked to cystic fibrosis and other lung diseases
April 15, 2024
Journal of the American Chemical Society differentiates EVQ-218 nanoparticle as a new form of silver; holds promise for widespread medical applications
EVQ-218 is the first stable, non-emissive, pure metal metamaterial on par with NIST standards.
February 22, 2024
EVOQ announces that its antimicrobial medical device platform demonstrates success against the leading cause of healthcare-associated infections
Novel metamaterial platform shows efficacy against antimicrobial resistance; potential to disrupt the $29 billion catheter market